Navigation Links
Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial
Date:1/27/2009

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today preliminary progression-free survival (PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone that show patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, p < 0.01, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS was a prospectively defined secondary endpoint in the study.

"We always believed the effectiveness of pixantrone would translate into a meaningful difference for patients with relapsed aggressive NHL and these dramatic and significant differences in PFS in this tough to treat group of patients provides that evidence," stated James A. Bianco, M.D. Chief Executive Officer of CTI. "Pixantrone is the first agent in this patient population to demonstrate a significant and meaningful PFS advantage. We believe these data will support a priority review designation on our New Drug Application (NDA) once we share them with the Food and Drug Administration (FDA)."

The Company had previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission. Additionally, pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) (26/70 (37.1%) for pixantrone arm compared to 10/70 (
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. Demand for VScan Dengue Fever Test Kits Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Electrophysiologist Kevin Makati, ... traveled to Boston, MA ... 2015 Heart Rhythm Society conference. These scientific sessions ... on the ideas, people and technology that propel ... a hybrid, minimally invasive cardiac operation that combines ...
(Date:5/22/2015)... and KING OF PRUSSIA, Pa. , May ... has awarded CSL Behring its 2015 Corporate Leadership ... to advancing science and improving the care of the bleeding ... , CEO and Managing Director, CSL Limited, during the NHF ... on May 21. "The National Hemophilia Foundation ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Pharmaceutical Companies, Inc. (NYSE: PRX ) announced today ... on Thursday, May 5, 2011 at 9:00 AM ET to ... its financial results on May 5, 2011 before the market ... made via the Company,s website at www.parpharm.com .Dial-in InformationDomestic: ...
... that a new market research report is available in ... 2011-2021 http://www.reportlinker.com/p0470100/World-Influenza-Vaccines-Market-2011-2021.html ... answers to benefit your work? Our new report shows ... influenza vaccines from 2009 to 2021.  There, ...
Cached Medicine Technology:Reportlinker Adds World Influenza Vaccines Market 2011-2021 2Reportlinker Adds World Influenza Vaccines Market 2011-2021 3Reportlinker Adds World Influenza Vaccines Market 2011-2021 4Reportlinker Adds World Influenza Vaccines Market 2011-2021 5Reportlinker Adds World Influenza Vaccines Market 2011-2021 6Reportlinker Adds World Influenza Vaccines Market 2011-2021 7Reportlinker Adds World Influenza Vaccines Market 2011-2021 8Reportlinker Adds World Influenza Vaccines Market 2011-2021 9Reportlinker Adds World Influenza Vaccines Market 2011-2021 10Reportlinker Adds World Influenza Vaccines Market 2011-2021 11Reportlinker Adds World Influenza Vaccines Market 2011-2021 12Reportlinker Adds World Influenza Vaccines Market 2011-2021 13Reportlinker Adds World Influenza Vaccines Market 2011-2021 14Reportlinker Adds World Influenza Vaccines Market 2011-2021 15Reportlinker Adds World Influenza Vaccines Market 2011-2021 16Reportlinker Adds World Influenza Vaccines Market 2011-2021 17Reportlinker Adds World Influenza Vaccines Market 2011-2021 18
(Date:5/25/2015)... May 25, 2015 According to a ... market growth in hip external fixation market is driven ... U.S. population and advancements in infection prevention technologies. As ... fractures are currently accounting for the largest total number ... with falls and accidents. As a result, the average ...
(Date:5/25/2015)... May 25, 2015 Join Fiona's Soccer Camp ... two-hour instructional clinic. Irish National Player, Fiona O'Sullivan will ... them a taste of her coaching style. Fiona has three ... Camps in Novato are at Lynwood Elmentary School (June 15-19) ... High School - June 6th, 2015 - 1:00-3:00pm. Bring a ...
(Date:5/24/2015)... Pacific Prime has announced that they have launched the ... cost of individual international health insurance. Titled: The Cost of Health ... of health insurance in six top expat destinations, which are also ... Hong Kong , Singapore , China , ... the UK , Article 2 presents an in-depth look ...
(Date:5/24/2015)... May 24, 2015 Scientists with Cardno ... on air quality compliance issues that may have raised ... Surviving Mesothelioma has just posted an article on the ... , The group found airborne asbestos levels well above ... between 1984 and 2011. , “Asbestos compliance sampling data ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
Breaking Medicine News(10 mins):Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 3Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Medicx Media Solutions Expands Executive Team 2
... News) -- Intensive control of blood sugar levels reduces ... diabetics, new research indicates. However, the evidence did ... actually developing severe kidney disease. The two signs ... conditions known as microalbuminuria and macroalbuminuria. These are characterized ...
... (May 29, 2012) Researchers from South Korea, Sweden, ... to restore neuron function to parts of the brain ... pluripotent stem cells into animal models. Induced ... human somatic cells such as skin, and can be ...
... May 29, 2012 Older adults who don,t get ... exposure may be at increased risk of developing mobility ... Baptist Medical Center. , "This is one of the first ... the onset of new mobility limitations or disability in older ...
... genetic disorders have uncovered insights into those diseases ... divide. Focusing on the cohesin complex, a group ... pairs, scientists have discovered mutations that disrupt cohesin, ... cohesinopathies. "We are learning more about how ...
... May 29, 2012 -- The discovery of a mummified ... scientific team to conduct a genetic analysis on a liver ... C2 sequence common in Southeast Asia. Additional analysis ... model to study the evolution of chronic hepatitis B and ...
... Texas For 50 years scientists have been unsure how the ... basic innate immune responses. That mystery has now been solved, thanks ... The answers may help clear the way for a ... such as V. cholerae , but instead disable their defenses ...
Cached Medicine News:Health News:Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study 2Health News:Researchers restore neuron function to brains damaged by Huntington's disease 2Health News:Older adults may need more vitamin D to prevent mobility difficulties 2Health News:Mutations impair childhood growth and development by disrupting organization of chromosome pairs 2Health News:16th-century Korean mummy provides clue to hepatitis B virus genetic code 2Health News:50-year cholera mystery solved 2
... dilution nebulizer allows the clinician to deliver up ... into the side port for precise high flow ... for normal flow patients, delivers 8-12 lpm in ... side port. For your high flow needs, DHD ...
Rotary Piston Mini Nebulizer...
... Solight® Forceps Lighting System is a ... where it's needed most---in small and deep ... fiber-optic cable and stainless steel light rod ... forceps while minimizing heat conduction. The system ...
... HELION family consists of four models in ... - to ensure you find the right ... singly or in a combination of two ... the standard design with an on/off switch ...
Medicine Products: